Jennison Associates LLC Allakos Inc. Transaction History

Jennison Associates LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$5.08 - $9.81 $1.37 Million - $2.65 Million	-270,532 Closed	0 $0
Q4 2021 Feb 08, 2022	BUY	$8.55 - $111.89 $862,600 - $11.3 Million	100,889 Added 59.47%	270,532 $2.65 Million
Q3 2021 Nov 09, 2021	BUY	$76.53 - $110.43 $4.47 Million - $6.44 Million	58,351 Added 52.43%	169,643 $18 Million
Q1 2021 May 11, 2021	BUY	$109.73 - $153.66 $12.2 Million - $17.1 Million	111,292 New	111,292 $12.8 Million
Q1 2019 May 10, 2019	SELL	$33.79 - $51.99 $9.94 Million - $15.3 Million	-294,194 Closed	0 $0
Q4 2018 Feb 06, 2019	SELL	$31.59 - $62.65 $1.5 Million - $2.98 Million	-47,608 Reduced 13.93%	294,194 $15.4 Million
Q3 2018 Nov 08, 2018	BUY	$31.25 - $47.64 $10.7 Million - $16.3 Million	341,802 New	341,802 $15.4 Million

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $91.5M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Jennison Associates LLC with notifications on news.